Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 33Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 11Triple Negative Breast Neoplasms 3Recurrence 3Esophageal Squamous Cell Carcinoma 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Unspecified Adult Solid Tumor, Protocol Specific 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Primary Breast Cancer 1Pathologic Residual Cancer Cells 1Ovarian Neoplasms 1Osteosarcoma 1Nonhematologic Malignancies 1Non-small Cell Lung Cancer Stage â…¡ 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplasms, Connective and Soft Tissue 1Neoplasm Metastasis 1NSCLC 1

Interventions

Vinorelbine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pathologic Residual Cancer Cells × Vinorelbine × Clear all
NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Shandong Cancer Hospital and Institute

Phase 2 Unknown
200 enrolled

Pathologic Residual Cancer Cells

Data powered by HemOnc (CC BY 4.0) Colophon âš¡